Biotek-snakken — August 2022
-
Som tidligere nævnt går de efter et selskab der vil udvikle RPT93 bredt og serielt, for ellers ønsker de at tage AD og astma indikationerne længere frem, før de laver en aftale. Deres CEO Brian Wong sagde tidligere, at baren var høj hvis de skulle have nogen ind nu.
-
bluebird bio Announces FDA Approval of ZYNTEGLO
, the First Gene Therapy for People with Beta-Thalassemia Who Require Regular Red Blood Cell Transfusions https://investor.bluebirdbio.com/news-releases/news-release-details/bluebird-bio-announces-fda-approval-zynteglor-first-gene-therapy -
Findes der ExpreS2ion Biotech Holding AB aktionærer her på ProInvestor? hvad tænker i om de kommende 6-12 måneder?
-
ExpreS2ion: Breast cancer HER2 vaccine i klinikken omkring 2023, blockbuster potentiale. Godt nok kun 1/3 af Covid vaccinen i størrelse, men 100% ejet af Expres2ion. Så jeg tænker at holde dem til efter både covid og breast cancer resultater, hvor sidstnævnte nok ikke lige lander indenfor 6-12 måneder.
-
@DevOp, så har jeg købt en lottokupon, nu må jeg læse lidt op lektion
-
3 Biopharmas on Buyout Watch https://www.proinvestor.com/investornyt/869514/3-biopharmas-on-buyout-watch
-
STENOCARE starting sales in Australia https://www.proinvestor.com/boards/105553
-
2cureX - interim report for H1 2022 https://www.proinvestor.com/boards/105587
-
InvestorBAVA: ExpreS2ion er blevet lidt mere specifikke for breast cancer vaccinen i halvårsrapporten. Nu siger de filing af clinical study H2 2023 og start 2024. Håber, at de lykkes med vaccinen. In vivo resultaterne i mus ser i hvert fald særdeles lovende ud.
-
Zymeworks targeting cancer with next-gen multifunctional biotherapeutics - BioTuesdays
Zymeworks (NYSE:ZYME) is leading a paradigm shift developing next-generation multifunctional antibodies and antibody drug conjugates, with an initial focus on HER2-targeted therapies to treat cancer.
BioTuesdays (biotuesdays.com)
-
“We have legacy partnerships and future milestones coming to us, which we could monetize with someone else for upfront liquidity and pass those future payments on to a financing partner,” he adds. “We hope to announce something about that later this year.”
-
Mød Genmab A/S Vice President, Head of Investor Relations Andrew Carlsen i en online Q&A session om selskabet og Q2 rapporten mandag d. 29. August kl. 15.00.
Moderator: Helge Larsen.Spørgsmål skal stilles på forhånd på engelsk i Q&A chatten. Deadline mandag kl. 12.
Tilmelding på link.
-
Biotech Stocks Facing FDA Decision In September https://www.proinvestor.com/investornyt/871985/biotech-stocks-facing-fda-decision-in-september
-
Trancript fra Q&A med CEO Adam Stensberg/Zealand Pharma Q2 afholdt i går kl. 15. https://www.proinvestor.com/ir/q-and-a/dk
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind